Biofrontera Inc. cash flow to debt ratio of -216.86% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Biofrontera Inc.'s free cash flow has decreased 29.36% from $-10.33M last year to $-13.36M, signaling decreasing performance

Biofrontera Inc.'s debt to equity ratio is 1.27, which means that the company's assets are unhealthy financed, signaling financial risk.

Biofrontera Inc.'s debt has increased relative to shareholder equity from 1.11 last year to 1.27 today, signaling weakened financials

Biofrontera Inc. has a net cash position, so leverage is healthy.

Biofrontera Inc.'s interest coverage ratio is -40.36, which means that the company struggles to meet interest obligations, signaling financial risk.

Biofrontera Inc.'s profit margin has increased (-46.10%) in the last year from -47.61% to -25.66%, signaling increasing performance

Biofrontera Inc.'s short-term assets of $18.08M exceed its short-term liabilities of $11.89M

Biofrontera Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Biofrontera Inc.'s return on equity of -476.72%, is lower than 15.00%, indicating bad performance

Biofrontera Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Biofrontera Inc. has insufficient public price history to evaluate earnings stability.

Biofrontera Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Biofrontera Inc. has negative free cash flow, indicating cash burn

Biofrontera Inc.'s yearly earnings has increased -40.67% since last year from $-17.76M to $-10.54M, signaling increasing performance

Biofrontera Inc.'s yearly revenue has increased 11.80% since last year from $37.30M to $41.70M, signaling increasing performance

ROIC -62.07% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Biofrontera Inc.'s 3-year revenue CAGR of 13.30% is positive, indicating growing revenue over the past 3 years

Biofrontera Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Biofrontera Inc. has insufficient public price history to evaluate ROE consistency.

Biofrontera Inc. has insufficient data to evaluate this check.

Biofrontera Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Biofrontera Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Biofrontera Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Biofrontera Inc. has insufficient data to evaluate this check.

Biofrontera Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Biofrontera Inc. has a price-to-book ratio of 2.33x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Biofrontera Inc. has a price-to-sales ratio of 0.33x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue